Detalhe da pesquisa
1.
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
N Engl J Med
; 390(19): 1781-1792, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587247
2.
VLDL Biogenesis and Secretion: It Takes a Village.
Circ Res
; 134(2): 226-244, 2024 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38236950
3.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med
; 387(21): 1923-1934, 2022 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342113
4.
Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans.
Arterioscler Thromb Vasc Biol
; 44(6): 1407-1418, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695168
5.
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.
Curr Opin Lipidol
; 35(3): 157-161, 2024 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38465912
6.
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion.
Hepatology
; 78(5): 1418-1432, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053190
7.
Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3).
Arterioscler Thromb Vasc Biol
; 43(3): 388-398, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36579649
8.
Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort.
J Lipid Res
; 64(3): 100336, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706955
9.
TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk.
FASEB J
; 36(3): e22185, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133032
10.
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Arterioscler Thromb Vasc Biol
; 42(1): e48-e60, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647487
11.
The year in cardiovascular medicine 2021: dyslipidaemia.
Eur Heart J
; 43(8): 807-817, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34974612
12.
LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials.
J Lipid Res
; 63(1): 100148, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774485
13.
Hepatocytes Deficient in Nuclear Envelope Protein Lamina-associated Polypeptide 1 are an Ideal Mammalian System to Study Intranuclear Lipid Droplets.
J Lipid Res
; 63(10): 100277, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36100089
14.
Correction: Personalized glucose forecasting for type 2 diabetes using data assimilation.
PLoS Comput Biol
; 17(8): e1009325, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415908
15.
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
Eur Heart J
; 42(47): 4791-4806, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34472586
16.
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides.
Curr Opin Lipidol
; 32(3): 200-206, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33883445
17.
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Circulation
; 141(8): 624-636, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707832
18.
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Cardiovasc Diabetol
; 20(1): 13, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33413345
19.
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Cardiovasc Diabetol
; 20(1): 125, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158057
20.
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
Diabetes Obes Metab
; 23(12): 2763-2774, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463415